TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier

As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain barrier...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shuo, Li, Yumeng, Chen, Jinqin, Zhang, Yue, Tao, Xinling, Dai, Qiuyun, Wang, Yutian, Li, Shupeng, Dong, Mingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562543/
https://www.ncbi.nlm.nih.gov/pubmed/31083641
http://dx.doi.org/10.3390/md17050286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562543/
https://www.ncbi.nlm.nih.gov/pubmed/31083641
http://dx.doi.org/10.3390/md17050286

Ejemplares similares